Phio Pharmaceuticals Corp. (PHIO) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
PHIO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PHIO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export PHIO earnings history in CSV or JSON format
Free sign-in required to download data
Phio Pharmaceuticals Corp. (PHIO) Earnings Overview
As of May 8, 2026, Phio Pharmaceuticals Corp. (PHIO) reported trailing twelve-month net income of -$8M, reflecting -59.3% year-over-year growth. The company earned $-1.45 per diluted share over the past four quarters.
Looking at the long-term picture, PHIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2024.
Phio Pharmaceuticals Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), ARWR (-$301M net income, -0.2% margin), ALNY ($577M net income, 8.4% margin), PHIO has comparable earnings metrics. Compare PHIO vs SRPT →
PHIO Earnings vs Peers
Earnings metrics vs comparable public companies
PHIO Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$9M | -21.7% | $0 | $-1.45 | - | - |
| 2024 | -$7M | +34.0% | -$7M | $-0.91 | - | - |
| 2023 | -$11M | +5.7% | -$11M | $-46.76 | - | - |
| 2022 | -$11M | +13.6% | -$11M | $-89.61 | - | - |
| 2021 | -$13M | -51.1% | -$14M | $-111.32 | - | - |
| 2020 | -$9M | +1.3% | -$9M | $-207.25 | - | - |
| 2019 | -$9M | -21.0% | -$9M | $-2074.18 | -42419.0% | -42795.2% |
| 2018 | -$7M | +40.9% | -$7M | $-6218.35 | -5333.3% | -5336.2% |
| 2017 | -$12M | -38.4% | -$14M | $-32801.22 | -83013.3% | -93746.7% |
| 2016 | -$9M | +12.0% | -$9M | $-79282.81 | -47336.8% | -47447.4% |
See PHIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHIO — Frequently Asked Questions
Quick answers to the most common questions about buying PHIO stock.
Is PHIO growing earnings?
PHIO EPS fell to $-1.45, with earnings declining -59.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-8M.
What are PHIO's profit margins?
Phio Pharmaceuticals Corp. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PHIO's earnings?
PHIO earnings data spans 2011-2025. The declining earnings trend is -59.3% YoY. Historical data enables comparison across business cycles.